The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThe European Commission has granted approval for Amgen's UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. This significant regulatory milestone introduces a new targeted therapeutic option, offering a first-in-class approach for durable disease control. UPLIZNA® stands out with its convenient twice-yearly maintenance dosing schedule. The decision is underpinned by robust data from the MINT study, which demonstrated substantial improvements in gMG symptoms. Furthermore, the study highlighted the potential for reducing long-term steroid use among patients. This approval is expected to positively impact Amgen's market position and revenue streams within the specialized pharmaceuticals sector.